Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 in Recurrent/Progressive Glioblastoma
NCT01122901Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RO4929097 in glioblastoma (GBM), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
RO4929097
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01122901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122901.